A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
An Ipsos MORI poll, commissioned by the League Against Cruel Sports (LACS), found 84% of the public do not want a return to fox hunting.
As Birmingham bids for the Commonwealth Games, we have been looking at sporting venues in the city which could be involved in the event.
Birmingham is bidding to host the 2026 Commonwealth Games, with those involved calling on the entire region to back it.